Skip to main content
VRDN logo

VRDN · Viridian Therapeutics, Inc.DE

Track VRDN — free
$29.96 -1.48 (-4.71%) At close · Nov 20
Market Cap
$3.40B
Shares
113.56M
Volume · Nov 20 1.75M Avg daily vol (3M) 2.13M

Price & Indicators

 

Key stats

Close
$29.96
Fri 20 Nov
Open
$31.12
Fri 20 Nov
Average volume, 30 days
2.7M
shares a session
Short interest
17.0M
15.0% of shares · 9.1 days to cover
Day range
$29.87$31.75
Open $31.12 Close $29.96
52-week closing range
$13.30$33.78
Close $29.96 11.3% under the high
Short volume, last session
48%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Jan 2020 to Nov 2026

Up next

May 4, 2027 Est · unconfirmed · in 23 wks

Latest documents

2026
Nov 9
Current report 8-K
VRDN-008 delivers 74% peak IgG reduction in phase 1

Viridian Therapeutics reported positive phase 1 results for VRDN-008, including 74% peak IgG reduction and an extended half-life of 15–18 days. It plans a pivotal MG trial in mid-2027, pending regulatory feedback.

Regulation FD disclosure, Other events
5 source passages
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. VRDN-008 demonstrated deep and sustained IgG reduction through 8 weeks after dosing in healthy volunteers, with 74% IgG reduction at peak. VRDN-008 demonstrated an extended half-life of 15–18 days, up to 6x longer than the first-generation Fc fragments. VRDN-008 demonstrated a safety profile that spared albumin and LDL and was generally well-tolerated, with no serious adverse events or dose-limiting toxicities in the trial. Viridian plans to rapidly advance VRDN-008 into pivotal development, including initiating at least one registrational clinical trial in 2027, starting with MG in mid-2027, pending regulatory feedback. Open the document at this passage
Nov 4
Earnings call
LUMVOA launch generated $24.7 million from more than 100 starts

Viridian’s LUMVOA launch generated $24.7 million in net product revenue, with more than 100 patients starting treatment. Broad payer coverage is targeted six to nine months from launch, and cash, cash equivalents and marketable securities totaled just over $955 million.

4 source passages
As mentioned, Lumvoa generated $24.7 million in net product revenue in its first quarter on the market. More than 100 patients were being treated with limboa at the end of the quarter. we're on track to achieve broad coverage for LIMVOA on our estimated timeline of six to nine months from launch. We ended the quarter with just over $955 million in cash, cash equivalents, and marketable securities on our balance sheet. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Lumvoa launches with $24.7 million in quarterly product revenue

Viridian Therapeutics launched Lumvoa in the United States after FDA approval in June 2026, generating $24.7 million in product revenue during the third quarter of 2026. More than 100 patients had started therapy as of September 30, 2026.

Revenue $25.75M ▼ 63.5% Net loss $101.21M
Read from the MD&A section
3 source passages
Following approval, we launched veligrotug in the United States under the trade name Lumvoa with commercial launch efforts focused on reaching target prescribers, enabling reliable access for patients, supporting physician offices and infusion centers, and engaging effectively with payors. Product revenue, net was $24.7 million for the three months ended September 30, 2026. As of September 30, 2026, more than 100 patients had started therapy with veligrotug in the United States. Open the document at this passage
Nov 4
Current report 8-K
Lumvoa earns $24.7 million; elegrobart BLA advances

Viridian Therapeutics, Inc. reported $24.7 million in Lumvoa net product revenue for the third quarter ended September 30, 2026, and $955.2 million in cash as of September 30, 2026. Elegrobart’s BLA submission remains on track for the first quarter of 2027.

Financial results
5 source passages
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026. Lumvoa generated $24.7 million in net product revenue; Cash, cash equivalents, and marketable securities were $955.2 million as of September 30, 2026. Elegrobart: BLA submission on track for Q1 2027 Viridian expects to submit a BLA to the U.S. FDA for elegrobart in TED in Q1 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$26.31M
Trailing 12 months
Net income (TTM)
−$453.58M
Trailing 12 months
Revenue growth YoY
-63.5%
Year over year
Operating margin
-1,781.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$191.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+23.1%
Year over year · more shares
Price change (1Y)
+1.7%
Trailing year
Short interest
15.0%
Latest settlement · 9.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Lumvoa exceeded launch expectations with $24.7 million of net product revenue and more than 100 patients on therapy; payer policies covered 30% of covered lives, and a permanent J-code was assigned effective January 1, 2027. Elegrobart’s BLA and VRDN-292 and VRDN-008 milestones remain on track, while SG&A and net loss increased and launch durability remains uncertain.

Bullish
  • + Patient and physician enthusiasm was translating into meaningful Lumvoa launch momentum.
  • + Lumvoa policies covered 30% of covered lives at September-end, with broad coverage targeted within six to nine months of launch.
  • + Existing cash and anticipated future commercial revenues were expected to fund current business plans through profitability.
Bearish
  • − The durability of Lumvoa’s early launch remains unproven and must be observed over subsequent quarters.
  • − Payer policy adoption takes time, with differing payer decision timelines.
  • − The J-code transition can create cash-flow issues for infusion centers, and Viridian provided relief through extended payment terms reflected in accounts receivable.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +39%
above
Price vs 50-day avg +27%
above
RSI (14) 64
neutral
MACD trend Negative
52-week position 81%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +34%
trailing
6-month return +89%
trailing
YTD return −4%
this year
Relative strength +98%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $24 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +42 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.01% of shares out · ▼ -5.3% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
236 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Weak
Revenue growth −12%
Y/Y
EPS growth −31%
Y/Y
Free cash flow $-276.9M
Balance sheet $79.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −61%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+39% Bullish
Price vs 50-day avg
+27% Bullish
RSI (14)
64 Neutral
MACD trend
Negative Bearish
52-week position
81% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $24 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +42 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.01% of shares out · ▼ -5.3% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
236 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $30 · 81% Range high $34
vs 200-day avg +39% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Shares of common stock outstanding on an as-converted basis 125,636,093 As of September 30, 2026 —
Core prescribing physicians 2,000 as of July 31, 2026 —
Core prescribing physicians engaged 95% as of July 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VRDN
Viridian Therapeutics, Inc.DE
this stock
$3.40B -3.7% -12.0% — 15.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
236
% held
120.9%
Net QoQ
+1.2M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
264
View
Short & Settlement
Short Interest Falling
Shares short
17.0M
Days to cover
9.1d
Change
-960.1K sh
View
Short Volume
Short vol %
48%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$124
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
45.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.7M
Net income (FY)
$-342.6M
EPS diluted
$-5.31
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
22

Viridian Therapeutics reported positive phase 1 results for VRDN-008, including 74% peak IgG reduction and an extended half-life of 15–18 days. It plans a pivotal MG trial in mid-2027, pending regulatory feedback.

View
Proposed Sales
Value
$348.2K
Shares
14.2K
Filed
Aug 19, 2026
View
Exempt Offerings
Offering
$91.0M
Filed
Nov 6, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Viridian Therapeutics Announces P…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
VRDN -3.0% +33.9% +88.8% +21.4% -3.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +5.6% +43.2% +98.0% +30.2% -4.9%
Key facts CIK 1590750 CUSIP 92790C104 13F (30d) 250 filings 226 filers Visit website Investor relations